WATERTOWN, Mass.--(BUSINESS WIRE)--Mariana Oncology, a biotechnology company focused on developing innovative radiopharmaceutical therapies for oncological diseases, today announced the appointment of Linda Bain as Chief Operating Officer and Chief Financial Officer. Bain brings extensive experience in strategic planning, finance, transactions, operations, investor relations, corporate communications and program management. She most recently served as Chief Financial Officer of Codiak BioSciences and has raised more than $700M in capital through venture, crossover rounds, IPOs and public equity financings over the past 10+ years.
“We are delighted to welcome Linda as the newest member of our executive team,” said Simon Read, Ph.D., Founder and Chief Executive Officer of Mariana Oncology. “Linda is an experienced and highly skilled professional with a strong track record of facilitating the capitalization of early- and late-stage biopharmaceutical companies. Her significant operational knowledge as well as business experience will be instrumental as we transition to a clinical stage company.”
In her new role, Bain will lead the development of Mariana’s financing strategy and growth plan as Mariana expands operations and prepares to enter the clinic.
"Radiopharmaceuticals are poised to transform treatment of cancer over the next decade. Mariana combines strong science, an outstanding leadership team, and an experienced group of investors to realize that opportunity,” said Linda Bain, Chief Operating and Financial Officer of Mariana Oncology. “I’m delighted to be part of such an innovative company and to help make Mariana’s therapies a reality for patients.”
Prior to joining Mariana and serving as CFO of Codiak BioSciences, Linda was CFO of Avalanche Biotechnologies, where she led a successful IPO and follow-on financing. Additionally, she served as Vice President of Finance, Business Operations, and Treasurer at bluebird bio, where she also led a successful IPO. Prior to bluebird bio, Linda held senior roles at Genzyme Corporation and was Vice President of Finance, Global Manufacturing and Operations, and Vice President of Finance, Genzyme Genetics. Earlier in her career, she held senior roles at Fidelity Investments, AstraZeneca, and Deloitte & Touche. Linda also currently serves on the Board of Directors of Arvinas, Autolus Therapeutics and Hemab Therapeutics.
About Mariana Oncology
Mariana Oncology is a fully integrated, next-generation radiopharmaceuticals company focused on pioneering a new class of targeted peptide-based radiopharmaceuticals that are both safe and effective. Mariana Oncology’s radiopharmaceuticals are composed of rationally designed conjugates against carefully selected biological targets, to deliver alpha and beta-emitting radionuclide payloads. Mariana Oncology’s mission is to revolutionize the use of radiopharmaceuticals in cancer.
